Showing 4301-4310 of 5957 results for "".
- Aurion Biotech Receives Approval in Japan for First Allogeneic Cell Therapy to Treat Corneal Endothelial Diseasehttps://modernod.com/news/aurion-biotech-receives-approval-in-japan-for-first-allogeneic-cell-therapy-to-treat-corneal-endothelial-disease/2481486/Aurion Biotech announced it has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for its novel cell therapy, Vyznova, for the treatment of bullous keratopathy of the cornea. The company believes this is the first regulatory approval in the world fo
- Visus Therapeutics Completes Enrollment in BRIO-I Phase 3 Trial of Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-completes-enrollment-in-brio-i-a-phase-3-clinical-trial-of-brimochol-pf-for-the-treatment-of-presbyopia/2481483/Visus Therapeutics announced it has completed patient enrollment and the last visit had been conducted in BRIO-I, a phase 3 trial for its lead asset, Brimochol PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia. “We are thrilled to have reache
- Nicox Announces Presentations of Additional NCX 470 Data at the Upcoming World Glaucoma Congresshttps://modernod.com/news/nicox-announces-presentations-of-additional-ncx-470-data-at-the-upcoming-world-glaucoma-congress/2481481/Nicox SA announced presentations of additional NCX 470 data at the 10th World Glaucoma Congress (WGC), which will be held from June 28 to July 1, 2023 in Rome, Italy. Details of the presentations: Poster Title: Effects of NCX 470, a Nitric Oxide (NO)-Donati
- NovaBay Pharmaceuticals Launches Avenova Eye Health Support to Comfort Dry Eyes and Promote Eye Healthhttps://modernod.com/news/novabay-pharmaceuticals-launches-avenova-eye-health-support-to-comfort-dry-eyes-and-promote-eye-health/2481480/NovaBay Pharmaceuticals announced the launch of OTC Avenova Eye Health Support oral supplement featuring a combination of MaquiBright, a nutrient-rich, antioxidant-dense extract of the superfruit maqui berry, and natural triglyceride omega-3 oils, designed to comfort dry eyes and s
- Researchers: Night Vision Tests in AMD Precisely Localize Disease Mechanismshttps://modernod.com/news/researchers-night-vision-tests-in-amd-precisely-localize-disease-mechanisms/2481479/Researchers at the University of Alabama at Birmingham discovered that night vision tests at a specific location in the retina will be suitable for assessing treatments and preventions for age-related macular degeneration (AMD), according to a university
- Aviceda Submits Investigational New Drug Application for AVD-104 for the Treatment of GA Associated with AMDhttps://modernod.com/news/aviceda-submits-investigational-new-drug-application-for-avd-104-for-the-treatment-of-ga-associated-with-amd/2481477/Aviceda Therapeutics announced that it has submitted an investigational new drug (IND) application to the FDA. The IND supports the use of its lead intravitreal ocular asset, AVD-104 (a novel glycan-coated nanoparticle), for the treatment of GA secondary to AMD. Aviceda previously announced
- Kuria Therapeutics Completes FDA Pre-IND Consultation for Topical Nrf2 Activator for Corneal Endothelial Diseasehttps://modernod.com/news/kuria-therapeutics-completes-fda-pre-ind-consultation-for-topical-nrf2-activator-for-corneal-endothelial-disease/2481475/Kuria Therapeutics has announced it has completed a pre-investigational new drug (IND) interaction with the FDA and received positive feedback on its development program for KTX-1161 for corneal endothelial disease. KTX-1161 is a topical ophthalmic solution formulation of SCO-
- HCP Cureblindness Acquires SightLife Internationalhttps://modernod.com/news/hcp-cureblindness-acquires-sightlife-international/2481471/HCP Cureblindness announced it is acquiring SightLife International, the global division of the SightLife organization, with full integration of systems, programs, and brand to come over the next 12 months. Financial terms of the deal were not disclosed. F
- Researchers Discover Therapeutic Target to Aid in Glaucoma Treatmenthttps://modernod.com/news/researchers-discover-therapeutic-target-to-aid-in-glaucoma-treatment/2481470/Indiana University School of Medicine researchers have identified a new therapeutic target that could lead to more effective treatment of glaucoma, according to an article posted on the university website.
- LumiThera Announces Sustained Vision Improvement for 24 Months in Dry AMD Subjects from US LIGHTSITE III Trialhttps://modernod.com/news/lumithera-announces-sustained-vision-improvement-for-24-months-in-dry-amd-subjects-from-us-lightsite-iii-clinical-trial-data/2481469/LumiThera announced 24-month data from its LIGHTSITE III multicenter clinical trial which demonstrated sustained vision improvement in dry age-related macular degeneration (AMD) subjects treated with the Valeda Light Delivery System. LIGHTSITE III, a prospective, double-masked